A simple method to identify undiagnosed drug-induced liver injury (DILI) and its application in oncology pharmacy practice

Abstract

Aims

To establish a simple method to identify chemotherapy-induced liver injury among oncological patients. To evaluate current clinical approach to elevated laboratory liver test results.

Methods

A total of 289 patients admitted to oncology department who had systemic chemotherapy episodes for cancer treatment from 1 January 2017 to 31 December 2017 were identified. With aid of healthcare information system, Hy's law was applied to laboratory liver test results to identify potential hepatocellular drug-induced liver injury cases. Medical record review was carried out among identified patients to exclude liver dysfunction of alternative causes. Current clinical approach to elevated laboratory liver tests was evaluated through medical record review.

Results

Of 289 patients who were treated by systemic chemotherapies, there were 123 patients with elevated laboratory liver tests, among which 8 patients were suspected as potential Hy's law cases. After medical record review, there were two patients determined with chemotherapy-associated liver injury, caused by 5-fluorouracil, leucovorin, irinotecan, and S-1 plus paclitaxel separately. Of eight potential Hy's law cases, seven (87.5%) patients were prescribed with ≥2 kinds of liver protectants and remained treated with traditional Chinese medicine for decoction.

Conclusions

A reliable and simple method to identify undiagnosed drug-induced liver injury was successfully established. An annual incidence of 0.69% of chemotherapy-associated liver injury in oncology department of the setting was found.

Keywords

Drug-induced liver injury chemotherapy Hy's law clinical pharmacy chemotherapy-associated liver injury

Get full access to this article

View all access options for this article.

References

Chalasani

Fontana

Bonkovsky

, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924–1934.e4.

Licata

Minissale

Calvaruso

, et al. A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. Eur Rev Med Pharmacol Sci 2017; 21: 112–121.

Björnsson

. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci 2016; 17: 224.

Shen

Liu

Shang

, et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology 2019; 156: 2230–2241.e11.

Vega

Verma

Beswick

, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the State of Delaware. Drug Saf 2017; 40: 783–787.

Bahirwani

Reddy

. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 2014; 34: 162–171.

Robinson

Wilson

Burt

, et al. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 4287–4299.

Chun

Laurent

Maru

, et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009; 10: 278–286.

Chalasani

Hayashi

Bonkovsky

, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014; 109: 950–966;. quiz 967.

10.

Church

Watkins

. Serum biomarkers of drug-induced liver injury: current status and future directions. J Dig Dis 2019; 20: 2–10.

11.

Regev

Björnsson

. Drug-induced liver injury: morbidity, mortality, and Hy's Law. Gastroenterology 2014; 147: 20–24.

12.

US Food and Drug Administration. Guidance for industry on drug-induced liver injury: premarketing clinical evaluation; availability, https://www.federalregister.gov/documents/2009/07/30/E9-18135/guidance-for-industry-on-drug-induced-liver-injury-premarketing-clinical-evaluation-availability (2009, accessed 28 April 2019).

13.

Senior

. Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges. Drug Saf 2014; 37: 9–17.

14.

Watkins

Desai

Berkowitz

, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH). Drug Saf 2011; 34: 243–252.

15.

McBane

Dopp

Abe

, et al. Collaborative drug therapy management and comprehensive medication management – 2015. Pharmacother J Hum Pharmacol Drug Ther 2015; 35: e39–e50.

16.

Ulcickas Yood

Bortolini

Casso

, et al. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. Pharmacoepidemiol Drug Saf 2015; 24: 427–434.

17.

Azad

Chang

Devuni

, et al. Real world experience of drug induced liver injury in patients undergoing chemotherapy. J Clin Gastroenterol Hepatol 2018; 2: 18.

18.

Choti

. Chemotherapy-associated hepatotoxicity: do we need to be concerned?. Ann Surg Oncol 2009; 16: 2391–2394.

19.

Vincenzi

Imperatori

Picardi

, et al. Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. Expert Rev Anticancer Ther 2015; 15: 971–976.

20.

de Jong

van der Bol

Mathijssen

RHJ

, et al. Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity. Cancer Biol Ther 2007; 6: 1364–1370.

21.

Toi

Miura

Shibasaki

, et al. Hepatic sinusoidal obstruction associated with S-1 plus cisplatin chemotherapy for highly advanced gastric cancer with paraaortic lymph node metastases: report of a case. Clin J Gastroenterol 2012; 5: 341–346.

22.

Search Livertox Database, https://livertox.nlm.nih.gov/index.html (accessed 29 May 2019).

23.

Costa

Rodrigues

Azevedo

, et al. Hepatotoxicity induced by paclitaxel interaction with turmeric in association with a microcystin from a contaminated dietary supplement. Toxicon 2018; 150: 207–211.

24.

Xie

J-D

Huang

Chen

D-T

, et al. Fentanyl enhances hepatotoxicity of paclitaxel via inhibition of CYP3A4 and ABCB1 transport activity in mice. PLoS One 2015; 10: e0143701.

25.

Chen

Zheng

Baade

, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–132.

26.

Guoyin

Hao

Min

, et al. Antihepatocarcinoma effect of Portulaca oleracea L. in mice by PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB pathway. Evid Based Complement Alternat Med 2017; 1: 1–11 .

27.

C-Y

Cherng

J-Y

Yang

Y-H

, et al. Danshen improves survival of patients with advanced lung cancer and targeting the relationship between macrophages and lung cancer cells. Oncotarget 2017; 8: 90925–90947.

28.

Gill

Navgeet Kumar

. Ganoderma lucidum targeting lung cancer signaling: a review. Tumour Biol 2017; 39: 1010428317707437.

29.

Moriyama

Hinode

Yoshioka

, et al. Impact of the use of Kampo medicine in patients with esophageal cancer during chemotherapy: a clinical trial for oral hygiene and oral condition. J Med Invest 2018; 65: 184–190.

30.

Chu

Shen

, et al. Pien Tze Huang alleviates 5-fluorouracil-induced intestinal mucositis in CT-26 tumor-bearing mice. Exp Ther Med 2017; 14: 2291–2297.

31.

Hung

Y-C

Chin

C-Y

Lee

Y-C

, et al. Clinical experience of Chinese herbal medicine ameliorates dermatologic events from epidermal growth factor receptor inhibitors for lung cancer: a case series. EXPLORE 2019; 15: 363–370.

32.

Pang

Yang

Hou

. Features and outcomes from a retrospective study of 570 hospitalized Chinese patients with drug-induced liver injury. Clin Res Hepatol Gastroenterol 2018; 42: 48–56.

33.

Peng

J-H

Y-Y

. Chinese herbal medicine-induced liver injury. J Clin Transl Hepatol 2014; 2: 170–175.

34.

Y-C

Mao

Y-M

Chen

C-W

, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017; 11: 221–241.

35.

Nathwani

Kaplowitz

. Drug hepatotoxicity. Clin Liver Dis 2006; 10: 207–217.

36.

Balducci

Goetz-Parten

Steinman

. Polypharmacy and the management of the older cancer patient. Ann Oncol 2013; 24: vii36–vii40.

37.

Real

Barnhill

Higley

, et al. Drug-induced liver injury: highlights of the recent literature. Drug Saf 2019; 42: 365–387.

38.

Robinson

Wilson

Burt

, et al. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 4287–4299.

39.

Robles-Diaz

Lucena

Kaplowitz

, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014; 147: 109–118.e5.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.09 MB